Becton, Dickinson and Co ((BDX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The BD SiteRite(TM) 9 Ultrasound System – Clinical Study aims to gather safety and performance data for the SiteRite 9 System, a post-market observational study. This data will support regional registrations and identify any unforeseen risks, focusing on patients needing Vascular Access Device (VAD) placement.
Intervention/Treatment: The study tests the BD SiteRite(TM) 9, a device used for ultrasound-guided vascular access device placement, assisting healthcare providers in IV cannulation through real-time visualization.
Study Design: This observational study employs a case-only model with a prospective time perspective. It focuses on patients undergoing the ultrasound-guided VAD placement procedure using the SiteRite 9 System.
Study Timeline: The study is set to begin in August 2025, with the last update submitted in July 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection.
Market Implications: As Becton, Dickinson and Co. advances with this study, positive outcomes could enhance their market position and investor confidence. The study’s results may influence stock performance, especially if the device proves to be a significant advancement over competitors in the medical device industry.
The study is ongoing, with further details available on the ClinicalTrials portal.